Literature DB >> 32051535

Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation.

Kaito Harada1, Shigeo Fuji2, Sachiko Seo3, Junya Kanda4, Toshimitsu Ueki5, Fumihiko Kimura6, Koji Kato7, Naoyuki Uchida8, Kazuhiro Ikegame9, Makoto Onizuka10, Ken-Ichi Matsuoka11, Noriko Doki12, Toshiro Kawakita13, Yasushi Onishi14, Shingo Yano15, Takahiro Fukuda16, Minoko Takanashi17, Yoshinobu Kanda18, Yoshiko Atsuta19,20, Masao Ogata21.   

Abstract

Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.

Entities:  

Mesh:

Year:  2020        PMID: 32051535     DOI: 10.1038/s41409-020-0821-9

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  43 in total

1.  Graft failure following reduced-intensity cord blood transplantation for adult patients.

Authors:  Hiroto Narimatsu; Masahiro Kami; Shigesaburo Miyakoshi; Naoko Murashige; Koichiro Yuji; Tamae Hamaki; Kazuhiro Masuoka; Eiji Kusumi; Yukiko Kishi; Tomoko Matsumura; Atsushi Wake; Shinichi Morinaga; Yoshinobu Kanda; Shuichi Taniguchi
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

2.  The incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantation.

Authors:  Yu-Qian Sun; Gan-Lin He; Ying-Jun Chang; Lan-Ping Xu; Xiao-Hui Zhang; Wei Han; Huan Chen; Yu-Hong Chen; Yu Wang; Feng-Rong Wang; Jing-Zhi Wang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Ann Hematol       Date:  2015-07-09       Impact factor: 3.673

Review 3.  Hematopoietic cell transplantation for aplastic anemia.

Authors:  Rajat Kumar; Carmem Bonfim; Biju George
Journal:  Curr Opin Hematol       Date:  2017-11       Impact factor: 3.284

4.  Risk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHI.

Authors:  T Cluzeau; J Lambert; N Raus; K Dessaux; L Absi; F Delbos; A Devys; M De Matteis; V Dubois; M Filloux; M Fort; F Hau; I Jollet; M Labalette; D Masson; B Mercier; B Pedron; P Perrier; C Picard; F Quainon; A Ramounau-Pigot; V Renac; P Van Endert; D Charron; R Peffault de la Tour; J L Taupin; P Loiseau
Journal:  Bone Marrow Transplant       Date:  2016-02-08       Impact factor: 5.483

Review 5.  Graft failure after allogeneic hematopoietic stem cell transplantation.

Authors:  Zehra Narli Ozdemir; Sinem Civriz Bozdağ
Journal:  Transfus Apher Sci       Date:  2018-04-18       Impact factor: 1.764

6.  Graft failure in the modern era of allogeneic hematopoietic SCT.

Authors:  R Olsson; M Remberger; M Schaffer; D M Berggren; B-M Svahn; J Mattsson; O Ringden
Journal:  Bone Marrow Transplant       Date:  2012-12-10       Impact factor: 5.483

7.  Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation.

Authors:  Andrea Bacigalupo; Maria Pia Sormani; Teresa Lamparelli; Francesca Gualandi; Domenico Occhini; Stefania Bregante; Anna Maria Raiola; Carmen di Grazia; Alida Dominietto; Elisabetta Tedone; Giovanna Piaggio; Marina Podesta; Barbara Bruno; Rosi Oneto; Anna Lombardi; Francesco Frassoni; Davide Rolla; Gianandrea Rollandi; Claudio Viscoli; Carlo Ferro; Lucia Garbarino; Maria Teresa Van Lint
Journal:  Haematologica       Date:  2004-10       Impact factor: 9.941

8.  Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysis.

Authors:  J Canaani; E Beohou; M Labopin; A Ghavamzadeh; D Beelen; R-M Hamladji; D Niederwieser; L Volin; M Markiewicz; R Arnold; G Mufti; G Ehninger; G Socié; N Kröger; M Mohty; A Nagler
Journal:  J Intern Med       Date:  2018-11-16       Impact factor: 8.989

9.  Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies.

Authors:  R F Olsson; B R Logan; S Chaudhury; X Zhu; G Akpek; B J Bolwell; C N Bredeson; C C Dvorak; V Gupta; V T Ho; H M Lazarus; D I Marks; O T H Ringdén; M C Pasquini; J R Schriber; K R Cooke
Journal:  Leukemia       Date:  2015-03-16       Impact factor: 11.528

Review 10.  Immunological Basis of Bone Marrow Failure after Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Stavroula Masouridi-Levrat; Federico Simonetta; Yves Chalandon
Journal:  Front Immunol       Date:  2016-09-16       Impact factor: 7.561

View more
  6 in total

Review 1.  Non-relapse cytopenias following allogeneic stem cell transplantation, a case based review.

Authors:  Ashvind Prabahran; Rachel Koldej; Lynette Chee; Jeff Szer; David Ritchie
Journal:  Bone Marrow Transplant       Date:  2022-07-23       Impact factor: 5.174

2.  Salvage HLA-haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for graft failure in non-malignant disorders.

Authors:  Michael H Albert; Mehtap Sirin; Manfred Hoenig; Fabian Hauck; Catharina Schuetz; Rajat Bhattacharyya; Polina Stepensky; Elad Jacoby; Tayfun Güngör; Rita Beier; Ansgar Schulz
Journal:  Bone Marrow Transplant       Date:  2021-05-09       Impact factor: 5.483

3.  Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation Supported by Third-Party Cord Blood Versus Human Leukocyte Antigen-Matched Sibling Peripheral Blood Stem Cell Transplantation in Hematologic Malignancy Patients.

Authors:  Tingting Cheng; Yan Chen; Yi Liu; Xia Ma; Cong Zeng; Xu Chen; Shiyu Wang; Yajing Xu
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738

4.  Haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood in hematologic malignancy patients: A report of 80 cases.

Authors:  Cong Zeng; Yan Chen; Juan Hua; Yi Liu; Ting-Ting Cheng; Xia Ma; Xu Chen; Shi-Yu Wang; Ya-Jing Xu
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

5.  Graft Failure in Patients With Hematological Malignancies: A Successful Salvage With a Second Transplantation From a Different Haploidentical Donor.

Authors:  Yu-Qian Sun; Yu Wang; Feng-Rong Wang; Chen-Hua Yan; Yi-Fei Cheng; Yu-Hong Chen; Yuan-Yuan Zhang; Ting-Ting Han; Wei Han; Pan Suo; Lan-Ping Xu; Xiao-Hui Zhang; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Med (Lausanne)       Date:  2021-06-04

6.  Effects of signaling pathway inhibitors on hematopoietic stem cells.

Authors:  Yuyu Jiang; Zhaofeng Xu; Na Ma; Lizhi Yin; Caiqin Hao; Jing Li
Journal:  Mol Med Rep       Date:  2020-11-12       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.